KBC Group NV Buys 4,396 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

KBC Group NV grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 107.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,471 shares of the company’s stock after acquiring an additional 4,396 shares during the quarter. KBC Group NV’s holdings in Hims & Hers Health were worth $205,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Quest Partners LLC grew its holdings in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares during the period. Stonekeep Investments LLC grew its holdings in shares of Hims & Hers Health by 5.5% in the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after buying an additional 882 shares during the period. CWM LLC increased its position in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Cadent Capital Advisors LLC raised its stake in Hims & Hers Health by 1.5% during the 4th quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after buying an additional 1,060 shares during the period. Finally, Raleigh Capital Management Inc. raised its stake in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the period. 63.52% of the stock is owned by institutional investors.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,343 shares of Hims & Hers Health stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $29.90, for a total transaction of $70,055.70. Following the completion of the transaction, the insider now owns 165,254 shares in the company, valued at approximately $4,941,094.60. This trade represents a 1.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the sale, the insider now owns 184,947 shares in the company, valued at $6,206,821.32. This represents a 1.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,156,332 shares of company stock worth $33,853,055 in the last ninety days. Insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Morgan Stanley assumed coverage on Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target for the company. Canaccord Genuity Group increased their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Piper Sandler lifted their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Monday, January 6th. BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $41.94 on Wednesday. The stock has a 50 day moving average price of $29.58 and a 200 day moving average price of $22.86. The stock has a market capitalization of $9.16 billion, a PE ratio of 95.32 and a beta of 1.35. Hims & Hers Health, Inc. has a 52 week low of $8.51 and a 52 week high of $41.98.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue was up 77.1% on a year-over-year basis. During the same period last year, the business earned ($0.04) earnings per share. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.